Key Updates in the Management of ER-Positive Breast Cancer - prIME Oncology
Clinical Spotlight
Clinical Spotlight

Key Updates in the Management of ER-Positive Breast Cancer

From the 2017 Annual Breast Cancer Meeting in San Antonio

Not a member of My prIME? Join now for instant access.

Update your treatment options with this thought-leader discussion, with associated slide deck and eNewsflash, featuring valuable updates and expert perspectives on exciting new developments in the management of breast cancer released at the 2017 Annual Breast Cancer Meeting in San Antonio.

Interactive Presentation

Interactive Presentation

Downloadable Slides

Downloadable Slides





Release Date

Release Date

Dec 12, 2017

Expiration Date

Dec 12, 2018

Abstract #GS2-05: First-line ribociclib vs placebo with goserelin and tamoxifen or a non-steroidal aromatase inhibitor in premenopausal women with hormone receptor-positive, HER2-negative advanced breast cancer: Results from the randomized phase III MONALEESA-7 trial

Abstract #P5-21-03: Palbociclib (PAL) + letrozole (LET) as first-line therapy in estrogen receptor–positive (ER+)/human epidermal growth factor receptor 2–negative (HER2−) advanced breast cancer (ABC): Efficacy and safety updates with longer follow-up across patient subgroups

Abstract #P5-21-02: Efficacy and safety of abemaciclib in patients with liver metastases in the MONARCH 1, 2, and 3 studies

Abstract #P1-17-03: Abemaciclib for the treatment of brain metastases secondary to hormone receptor-positive breast cancer

Abstract #GS6-02: The benefit of abemaciclib in prognostic subgroups: An exploratory analysis of combined data from the MONARCH 2 and 3 studies

Abstract #P2-09-10: Comprehensive gene expression biomarker analysis of CDK 4/6 and endocrine pathways from the PALOMA-2 study

Abstract #P1-14-05: Ribociclib dose recommendations for potential pharmacokinetic drug interaction and in special patient populations with organ impairment

Abstract #P1-09-01: A phase 1b study of abemaciclib plus pembrolizumab for patients with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) metastatic breast cancer (MBC)t

Abstract #GS2-07: MANTA – A randomized phase II study of fulvestrant in combination with the dual mTOR inhibitor AZD2014 or everolimus or fulvestrant alone in estrogen receptor-positive advanced or metastatic breast cancer

Abstract #GS4-07: Results from a randomized placebo-controlled phase 2 trial evaluating exemestane ± enzalutamide in patients with hormone receptor-positive breast cancer

Featured Experts

  • Robert Coleman, MD, FRCP, FRCPEMedical Director, prIME Oncology
    University of Sheffield
    Weston Park Hospital
    Sheffield, United Kingdom
  • Nadia Harbeck, MD, PhDUniversity of Munich
    Munich, Germany
  • Yen-Shen Lu, MDNational Taiwan University
    Taipei, Taiwan
  • Ahmed Saadeddin, MD, FRCRKing Abdulaziz Medical City
    Riyadh, Kingdom of Saudi Arabia

After successful completion of this educational activity, participants should be able to:

  • Summarize the clinical application of novel combinations of targeted and endocrine therapy for the first- and second-line treatment of ER-positive, HER2-negative advanced breast cancer
  • Select appropriate treatment combinations for ER-positive, HER2-negative breast cancer, and identify the optimal sequence of treatment options

This educational activity is supported by a grant from Novartis Pharma AG.

Independent Medical Education (IME)

This IME activity is organized by prIME Oncology. This activity provides content that is evidence-based, balanced, and free of commercial bias, with a primary objective to improve competence and performance of learners in order to improve patient care.


This enduring activity is provided by prIME Oncology.

Disclosure Information


Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Disclosure Regarding Unlabeled Use

This activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration or European Medicines Agency. Please refer to the official prescribing information for each product discussed for discussions of approved indications, contraindications, and warnings.